{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:58:16Z","timestamp":1790963896443,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple Myeloma (MM) is the second most common hematological malignancy, characterized by the accumulation of monoclonal plasmocytes in the bone marrow. Despite advancements with proteasome inhibitors, immunomodulatory agents, and CD38-targeting antibodies, MM remains largely incurable due to resistant clones and frequent relapses. The success of the proteasome inhibitor bortezomib (BTZ) in MM treatment highlights the critical role of the ubiquitin\u2013proteasome system (UPS) in this disease. Deubiquitinases (DUBs), which regulate protein stability, interactions, and localization by removing ubiquitin modifications, have emerged as promising therapeutic targets in various cancers, including MM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Through a comprehensive loss-of-function screen, we identified USP39 as a critical survival factor for MM cells. Gene Set Enrichment Analysis (GSEA) was employed to correlate USP39 mRNA levels with clinical outcomes in MM patients. USP39 protein expression was evaluated via immunohistochemistry (IHC) on bone marrow samples from MM patients and healthy controls. The impact of USP39 knockdown via SiRNA was assessed through in vitro assays measuring cellular metabolism, clonogenic capacity, cell cycle progression, apoptosis, and sensitivity to BTZ. Co-immunoprecipitation and deubiquitination assays were conducted to elucidate the interaction and regulation of ZEB1 by USP39. Finally, in vitro and in vivo zebrafish experiments were used to characterize the biological consequences of ZEB1 regulation by USP39.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our study found that elevated USP39 mRNA levels are directly associated with shorter survival in MM patients. USP39 protein expression is significantly higher in MM patient plasmocytes compared to healthy individuals. USP39 knockdown inhibits clonogenic capacity, induces cell cycle arrest, triggers apoptosis, and overcomes BTZ resistance. Gain-of-function assays revealed that USP39 stabilizes the transcription factor ZEB1, enhancing the proliferation and the trans-migratory potential of MM cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings highlight the critical role of the deubiquitinase USP39, suggesting that the USP39\/ZEB1 axis could serve as a potential diagnostic marker and therapeutic target in MM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-024-03241-2","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T22:21:17Z","timestamp":1735597277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation"],"prefix":"10.1186","volume":"43","author":[{"given":"Jessy","family":"Sirera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saharnaz","family":"Sarlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Teisseire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrine","family":"Carminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Savy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Brest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Juel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bontoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Ohanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Dufies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-4998","authenticated-orcid":false,"given":"Frederic","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"10272","key":"3241_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"issue":"2","key":"3241_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers. 2020;12(2):407. https:\/\/doi.org\/10.3390\/cancers12020407.","journal-title":"Cancers"},{"issue":"10","key":"3241_CR3","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Harousseau J-L, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343\u201357. https:\/\/doi.org\/10.1038\/s41375-019-0561-2.","journal-title":"Leukemia"},{"key":"3241_CR4","doi-asserted-by":"publisher","unstructured":"Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. J Biosci. 2006;31(1):137\u201355. https:\/\/doi.org\/10.1007\/BF02705243.","DOI":"10.1007\/BF02705243"},{"key":"3241_CR5","doi-asserted-by":"publisher","first-page":"831116","DOI":"10.3389\/fnmol.2022.831116","volume":"15","author":"APK Wodrich","year":"2022","unstructured":"Wodrich APK, Scott AW, Shukla AK, Harris BT, Giniger E. The unfolded protein responses in health, aging, and neurodegeneration: recent advances and future considerations. Front Mol Neurosci. 2022;15:831116. https:\/\/doi.org\/10.3389\/fnmol.2022.831116.","journal-title":"Front. Mol Neurosci"},{"issue":"1","key":"3241_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/imr.12236","volume":"263","author":"AA Sahasrabuddhe","year":"2015","unstructured":"Sahasrabuddhe AA, Elenitoba-Johnson KSJ. Role of the ubiquitin proteasome system in hematologic malignancies. Immunol Rev. 2015;263(1):224\u201339. https:\/\/doi.org\/10.1111\/imr.12236.","journal-title":"Immunol Rev"},{"issue":"8","key":"3241_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","volume":"130","author":"JL Harousseau","year":"2017","unstructured":"Harousseau JL, Attal M. How i treat first relapse of myeloma. Blood. 2017;130(8):963\u201373. https:\/\/doi.org\/10.1182\/blood-2017-03-726703.","journal-title":"Blood"},{"issue":"2","key":"3241_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"S Ito","year":"2020","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265. https:\/\/doi.org\/10.3390\/cancers12020265.","journal-title":"Cancers"},{"issue":"4","key":"3241_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2016.39","volume":"26","author":"KN Swatek","year":"2016","unstructured":"Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26(4):399\u2013422. https:\/\/doi.org\/10.1038\/cr.2016.39.","journal-title":"Cell Res"},{"key":"3241_CR10","doi-asserted-by":"publisher","unstructured":"Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004;1695(1-3):189\u2013207. https:\/\/doi.org\/10.1016\/j.bbamcr.2004.10.003.","DOI":"10.1016\/j.bbamcr.2004.10.003"},{"issue":"1","key":"3241_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","volume":"86","author":"TET Mevissen","year":"2017","unstructured":"Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86(1):159\u201392. https:\/\/doi.org\/10.1146\/annurev-biochem-061516-044916.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"3241_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","volume":"9","author":"H Lei","year":"2021","unstructured":"Lei H, Wang J, Hu J, Zhu Q, Wu Y. Deubiquitinases in hematological malignancies. Biomark Res. 2021;9(1):66. https:\/\/doi.org\/10.1186\/s40364-021-00320-w.","journal-title":"Biomark Res"},{"issue":"11","key":"3241_CR13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood.2020005199","volume":"137","author":"Y Xu","year":"2021","unstructured":"Xu Y, et al. Targeting the Otub1\/c-Maf axis for the treatment of multiple myeloma. Blood. 2021;137(11):1478\u201390. https:\/\/doi.org\/10.1182\/blood.2020005199.","journal-title":"Blood"},{"issue":"38","key":"3241_CR14","doi-asserted-by":"publisher","first-page":"40704","DOI":"10.18632\/oncotarget.5727","volume":"6","author":"S Hussain","year":"2015","unstructured":"Hussain S, Bedekovics T, Chesi M, Bergsagel PL. UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget. 2015;6(38):40704\u201318. https:\/\/doi.org\/10.18632\/oncotarget.5727.","journal-title":"Oncotarget"},{"issue":"7277","key":"3241_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08646","volume":"463","author":"M Schwickart","year":"2010","unstructured":"Schwickart M, Dixit VM. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463(7277):103\u20137.","journal-title":"Nature"},{"issue":"7","key":"3241_CR16","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1172\/JCI98765","volume":"128","author":"R Franqui-Machin","year":"2018","unstructured":"Franqui-Machin R, et al. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018;128(7):2877\u201393. https:\/\/doi.org\/10.1172\/JCI98765.","journal-title":"J Clin Invest"},{"key":"3241_CR17","doi-asserted-by":"publisher","first-page":"110068","DOI":"10.1016\/j.cellsig.2021.110068","volume":"85","author":"X Dong","year":"2021","unstructured":"Dong X, et al. USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma. Cell Signal. 2021;85:110068. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110068.","journal-title":"Cell Signal"},{"issue":"6","key":"3241_CR18","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3892\/or.2013.2798","volume":"30","author":"H Wang","year":"2013","unstructured":"Wang H, et al. Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro. Oncol Rep. 2013;30(6):2871\u20137. https:\/\/doi.org\/10.3892\/or.2013.2798.","journal-title":"Oncol Rep"},{"key":"3241_CR19","doi-asserted-by":"publisher","unstructured":"Xing Z, Sun F, He W, Wang Z, Song X, Zhang F. Downregulation of ubiquitin-specific peptidase 39 suppresses the proliferation and induces the apoptosis of human colorectal cancer cells. Oncol Lett, 2018, https:\/\/doi.org\/10.3892\/ol.2018.8061.","DOI":"10.3892\/ol.2018.8061"},{"issue":"23","key":"3241_CR20","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.3390\/ijms21238949","volume":"21","author":"J Yuan","year":"2020","unstructured":"Yuan J, et al. Knocking down USP39 inhibits the growth and metastasis of non-small-cell lung cancer cells through activating the p53 pathway. Int J Mol Sci. 2020;21(23):8949. https:\/\/doi.org\/10.3390\/ijms21238949.","journal-title":"Int J Mol Sci"},{"issue":"37","key":"3241_CR21","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1038\/s41388-019-0888-1","volume":"38","author":"K Ding","year":"2019","unstructured":"Ding K, et al. RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation. Oncogene. 2019;38(37):6414\u201328. https:\/\/doi.org\/10.1038\/s41388-019-0888-1.","journal-title":"Oncogene"},{"key":"3241_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2019.02.015","volume":"449","author":"J Wu","year":"2019","unstructured":"Wu J, et al. USP39 regulates DNA damage response and chemo-radiation resistance by deubiquitinating and stabilizing CHK2. Cancer Lett. 2019;449:114\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.015.","journal-title":"Cancer Lett"},{"issue":"11","key":"3241_CR23","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.4049\/jimmunol.1901384","volume":"205","author":"Y Peng","year":"2020","unstructured":"Peng Y, et al. USP39 serves as a deubiquitinase to stabilize STAT1 and sustains type I IFN\u2013induced antiviral immunity. J Immunol. 2020;205(11):3167\u201378. https:\/\/doi.org\/10.4049\/jimmunol.1901384.","journal-title":"J Immunol"},{"issue":"8","key":"3241_CR24","first-page":"3644","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu W, Sun T, Wang J, Li M, Liu C. USP39 facilitates breast cancer cell proliferation through stabilization of FOXM. Am J Cancer Res. 2022;12(8):3644\u201361.","journal-title":"Am J Cancer Res"},{"key":"3241_CR25","doi-asserted-by":"publisher","first-page":"101713","DOI":"10.1016\/j.tranon.2023.101713","volume":"34","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, et al. USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression. Transl Oncol. 2023;34:101713. https:\/\/doi.org\/10.1016\/j.tranon.2023.101713.","journal-title":"Transl Oncol"},{"issue":"8","key":"3241_CR26","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41418-021-00754-7","volume":"28","author":"X Li","year":"2021","unstructured":"Li X, et al. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma. Cell Death Differ. 2021;28(8):2315\u201332. https:\/\/doi.org\/10.1038\/s41418-021-00754-7.","journal-title":"Cell Death Differ"},{"key":"3241_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.biopha.2018.11.112","volume":"110","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Xu L, Li A, Han X. The roles of ZEB1 in tumorigenic progression and epigenetic modifications. Biomed Pharmacother. 2019;110:400\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.112.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3241_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/cells11040649","volume":"11","author":"D Greaves","year":"2022","unstructured":"Greaves D, Calle Y. Epithelial Mesenchymal Transition (EMT) and associated invasive adhesions in solid and haematological tumours. Cells. 2022;11(4):649. https:\/\/doi.org\/10.3390\/cells11040649.","journal-title":"Cells"},{"issue":"3","key":"3241_CR29","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1097\/HS9.0000000000000043","volume":"2","author":"B Soen","year":"2018","unstructured":"Soen B, Vandamme N, Berx G, Schwaller J, Van Vlierberghe P, Goossens S. ZEB proteins in leukemia: friends, foes, or friendly foes? HemaSphere. 2018;2(3):e43. https:\/\/doi.org\/10.1097\/HS9.0000000000000043.","journal-title":"HemaSphere"},{"key":"3241_CR30","doi-asserted-by":"publisher","unstructured":"Hamouda M-A, et al. The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget. 2014;5:6252\u201366. https:\/\/doi.org\/10.18632\/oncotarget.2193.","DOI":"10.18632\/oncotarget.2193"},{"issue":"1","key":"3241_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2527\/1991.69167x","volume":"69","author":"WE Berndtson","year":"1991","unstructured":"Berndtson WE. A simple, rapid and reliable method for selecting or assessing the number of replicates for animal experiments. J Anim Sci. 1991;69(1):67. https:\/\/doi.org\/10.2527\/1991.69167x.","journal-title":"J Anim Sci"},{"key":"3241_CR32","doi-asserted-by":"publisher","unstructured":"Richardson PG, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2005;352(24):2487\u201398. https:\/\/doi.org\/10.1056\/NEJMoa043445.","DOI":"10.1056\/NEJMoa043445"},{"issue":"26","key":"3241_CR33","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, et al. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609\u201317. https:\/\/doi.org\/10.1056\/NEJMoa030288.","journal-title":"N Engl J Med"},{"issue":"2","key":"3241_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/0008-5472.CAN-15-1926","volume":"76","author":"A Sacco","year":"2016","unstructured":"Sacco A, et al. Cancer cell dissemination and homing to the bone marrow in a Zebrafish model. Cancer Res. 2016;76(2):463\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1926.","journal-title":"Cancer Res"},{"key":"3241_CR35","doi-asserted-by":"publisher","unstructured":"Antao AM, Tyagi A, Kim K-S, Ramakrishna S. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics. Cancers, 2020;12(6):1579. https:\/\/doi.org\/10.3390\/cancers12061579.","DOI":"10.3390\/cancers12061579"},{"key":"3241_CR36","doi-asserted-by":"publisher","first-page":"e72879","DOI":"10.7554\/eLife.72879","volume":"11","author":"LM Doherty","year":"2022","unstructured":"Doherty LM, et al. Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes. eLife. 2022;11:e72879. https:\/\/doi.org\/10.7554\/eLife.72879.","journal-title":"eLife"},{"issue":"13","key":"3241_CR37","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.1002\/cam4.6103","volume":"12","author":"N Li","year":"2023","unstructured":"Li N, et al. Plasma cell myeloma with RAS\/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. Cancer Med. 2023;12(13):14293\u2013304. https:\/\/doi.org\/10.1002\/cam4.6103.","journal-title":"Cancer Med"},{"issue":"10","key":"3241_CR38","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1074\/jbc.M116.762757","volume":"292","author":"JM Fraile","year":"2017","unstructured":"Fraile JM, et al. USP39 deubiquitinase is essential for KRAS oncogene-driven cancer. J Biol Chem. 2017;292(10):4164\u201375. https:\/\/doi.org\/10.1074\/jbc.M116.762757.","journal-title":"J Biol Chem"},{"issue":"9","key":"3241_CR39","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41388-021-02167-9","volume":"41","author":"H Li","year":"2022","unstructured":"Li H, et al. Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1. Oncogene. 2022;41(9):1298\u2013308. https:\/\/doi.org\/10.1038\/s41388-021-02167-9.","journal-title":"Oncogene"},{"issue":"3","key":"3241_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan D, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes Bortezomib resistance. Cancer Cell. 2012;22(3):345\u201358. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.007.","journal-title":"Cancer Cell"},{"issue":"40","key":"3241_CR41","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1038\/onc.2017.172","volume":"36","author":"Y Song","year":"2017","unstructured":"Song Y, et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017;36(40):5631\u20138. https:\/\/doi.org\/10.1038\/onc.2017.172.","journal-title":"Oncogene"},{"issue":"7","key":"3241_CR42","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed Y, et al. Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)\u2013dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708\u201317. https:\/\/doi.org\/10.1182\/blood-2006-07-035857.","journal-title":"Blood"},{"issue":"1","key":"3241_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1196\/annals.1322.047","volume":"1028","author":"G Pagnucco","year":"2004","unstructured":"Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann NY Acad Sci. 2004;1028(1):390\u20139. https:\/\/doi.org\/10.1196\/annals.1322.047.","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"3241_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1349-7006.2009.01419.x","volume":"101","author":"M Iwatsuki","year":"2010","unstructured":"Iwatsuki M, et al. Epithelial\u2013mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101(2):293\u20139. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01419.x.","journal-title":"Cancer Sci"},{"key":"3241_CR45","doi-asserted-by":"publisher","first-page":"117503","DOI":"10.1016\/j.lfs.2020.117503","volume":"249","author":"Y Peng","year":"2020","unstructured":"Peng Y, et al. IGF-1 promotes multiple myeloma progression through PI3K\/Akt-mediated epithelial-mesenchymal transition. Life Sci. 2020;249:117503. https:\/\/doi.org\/10.1016\/j.lfs.2020.117503.","journal-title":"Life Sci"},{"key":"3241_CR46","doi-asserted-by":"publisher","unstructured":"Lemma S, et al. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology. 2013;62(2):326\u201333. https:\/\/doi.org\/10.1111\/his.12000.","DOI":"10.1111\/his.12000"},{"issue":"1","key":"3241_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ccell.2016.05.011","volume":"30","author":"V Stavropoulou","year":"2016","unstructured":"Stavropoulou V, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell. 2016;30(1):43\u201358. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.011.","journal-title":"Cancer Cell"},{"issue":"1","key":"3241_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","volume":"120","author":"IM Ghobrial","year":"2012","unstructured":"Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120(1):20\u201330. https:\/\/doi.org\/10.1182\/blood-2012-01-379024.","journal-title":"Blood"},{"issue":"24","key":"3241_CR49","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119(24):5782\u201394. https:\/\/doi.org\/10.1182\/blood-2011-09-380410.","journal-title":"Blood"},{"key":"3241_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canlet.2020.01.040","volume":"475","author":"CM Cheong","year":"2020","unstructured":"Cheong CM, et al. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Lett. 2020;475:99\u2013108. https:\/\/doi.org\/10.1016\/j.canlet.2020.01.040.","journal-title":"Cancer Lett"},{"key":"3241_CR51","unstructured":"Zhou Z, et al. USP51 promotes deubiquitination and stabilization of ZEB. p. 12."},{"issue":"6","key":"3241_CR52","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/1541-7786.MCR-22-0552","volume":"21","author":"L Sun","year":"2023","unstructured":"Sun L, Yu J, Guinney J, Qin B, Sinicrope FA. USP10 regulates ZEB1 ubiquitination and protein stability to inhibit ZEB1-mediated colorectal cancer metastasis. Mol Cancer Res. 2023;21(6):578\u201390. https:\/\/doi.org\/10.1158\/1541-7786.MCR-22-0552.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"3241_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41419-023-05699-y","volume":"14","author":"K Zeng","year":"2023","unstructured":"Zeng K, et al. USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma. Cell Death Dis. 2023;14(3):194. https:\/\/doi.org\/10.1038\/s41419-023-05699-y.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3241_CR54","doi-asserted-by":"publisher","first-page":"112884","DOI":"10.1016\/j.yexcr.2021.112884","volume":"409","author":"C Song","year":"2021","unstructured":"Song C, et al. USP18 promotes tumor metastasis in esophageal squamous cell carcinomas via deubiquitinating ZEB1. Exp Cell Res. 2021;409(1):112884. https:\/\/doi.org\/10.1016\/j.yexcr.2021.112884.","journal-title":"Exp Cell Res"},{"issue":"2","key":"3241_CR55","doi-asserted-by":"publisher","first-page":"404","DOI":"10.7150\/jca.48056","volume":"12","author":"D Ye","year":"2021","unstructured":"Ye D, Wang S, Huang Y, Wang X, Chi P. USP43 directly regulates ZEB1 protein, mediating proliferation and metastasis of colorectal cancer. J Cancer. 2021;12(2):404\u201316. https:\/\/doi.org\/10.7150\/jca.48056.","journal-title":"J Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03241-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T23:03:53Z","timestamp":1735599833000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03241-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3241"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03241-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All Zebrafish experiments were approved by the IRCAN Experimental Animal Ethical Committee<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}